Bitnomial Introduces Regulated Injective Futures to US Market

Bitnomial, a CFTC-regulated derivatives exchange, has officially launched monthly futures contracts for Injective (INJ). This marks the first time the Web3 financial ecosystem's native token has been available via a regulated US derivatives product. The launch is strategically timed to support the potential approval of a spot Injective ETF. Under SEC listing rules, a regulated futures market often provides the necessary price discovery and track record required for ETF eligibility. This development follows a filing by Canary Capital for a staked INJ ETF. The new contracts settle in INJ with monthly expiries. Traders can margin their positions using either US dollars or cryptocurrency through Bitnomial’s clearinghouse. While institutional clients have immediate access, retail traders are expected to gain access via the Botanical platform in the coming weeks. Bitnomial is expanding its altcoin footprint, having previously launched regulated futures for Aptos (APT) and XRP. The exchange operates as a trading venue, brokerage, and clearinghouse, navigating a complex regulatory landscape where most US-regulated futures remain limited to Bitcoin and Ether. The addition of INJ futures, along with planned perpetuals and options, increases institutional accessibility to the Injective Layer 1 blockchain. This infrastructure development could signal a broader trend of altcoin derivatives entering the regulated US sphere.